Sign in

Private company

Morphic Holding, Inc.

In its 2024 annual report the company says: “We are a biopharmaceutical company applying our proprietary insights into integrins to discover and develop a pipeline of potentially first-in-class oral small molecule integrin therapeutics. We are advancing our pipeline, including our lead product candidate, MORF-057, an orally administered α4β7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease, or IBD, an indication for which there is significant unmet need.”5 It is headquartered in Waltham, United States.2

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersWaltham, United States2
  • Incorporated inDE3
  • Business address35 Gatehouse Drive A2, Waltham, Ma 024513
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation2
  • LEI549300RWWOUFLHTY12242
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 55902142

See how the biggest companies compare on our leaderboards

We are a biopharmaceutical company applying our proprietary insights into integrins to discover and develop a pipeline of potentially first-in-class oral small molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. To date, no oral small molecule integrin therapies have been approved by the U.S. Food and Drug Administration, or FDA. Despite this, we believe our unique platform can unlock the potential to reliably generate high-quality oral molecules against specific integrin targets. The Morphic integrin technology platform, or MInT Platform, was created leveraging our unique understanding of integrin structure and function to develop novel product candidates designed to achieve the potency, high selecti…5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-34296.7%Operating margin6
-29192.9%Net margin6
-99.3%Revenue growth, 20236
-21.8%Return on equity6
-$113.6MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development100¢$140.4M
  • Income tax0¢$380.0K

Out of $521.0K in revenue.6 The company lost money this year.

Financial statements

Revenue7896$521.0K in 2023−84% since 2018
0$20.0M$40.0M$60.0M$80.0M2018: $3.4M$3.4M20182019: $17.0M$17.0M2019+406%2020: $44.9M$44.9M2020+165%2021: $19.8M$19.8M2021−56%2022: $70.8M$70.8M2022+258%2023: $521.0K$521.0K2023−99%
Operating income7896-$178.7M in 2023+626% since 2018
-$200.0M-$150.0M-$100.0M-$50.0M02018: -$24.6M-$24.6M20182019: -$47.0M-$47.0M2019+91%2020: -$47.2M-$47.2M2020+0%2021: -$95.8M-$95.8M2021+103%2022: -$63.4M-$63.4M2022−34%2023: -$178.7M-$178.7M2023+182%
Net income7896-$152.1M in 2023+538% since 2018
-$200.0M-$150.0M-$100.0M-$50.0M02018: -$23.8M-$23.8M20182019: -$43.3M-$43.3M2019+82%2020: -$45.0M-$45.0M2020+4%2021: -$95.5M-$95.5M2021+112%2022: -$59.0M-$59.0M2022−38%2023: -$152.1M-$152.1M2023+158%
Fiscal year2017201820192020202120222023
Revenue$3.4M7$17.0M8$44.9M9$19.8M6$70.8M6$521.0K6
Research and development$22.6M7$53.7M8$73.6M9$87.8M6$102.1M6$140.4M6
Operating expenses$115.6M6$134.2M6$179.2M6
Operating income-$24.6M7-$47.0M8-$47.2M9-$95.8M6-$63.4M6-$178.7M6
Interest$43.0K7
Income before tax-$95.5M6-$59.0M6-$151.7M6
Income tax$07$912.0K8-$570.0K9$06$67.0K6$380.0K6
Net income-$23.8M7-$43.3M8-$45.0M9-$95.5M6-$59.0M6-$152.1M6
Earnings per share-$2.698-$1.479-$2.676-$1.556-$3.596
Earnings per share (diluted)-$2.698-$1.479-$2.676-$1.556-$3.596
Shares (weighted, basic)35.8M shares638.1M shares642.4M shares6
Shares (weighted, diluted)35.8M shares638.1M shares642.4M shares6

Compare Morphic Holding, Inc. with another company

Corporate structure

Morphic Holding, Inc. is part of a group headed by Eli Lilly and Company. 164 entities, 54 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Morphic Holding, Inc.

  • Point72 Asset Management, L.P. Filed SC 13G/A on Morphic Holding, Inc., latest Nov 14, 2024 (3 filings since Oct 2, 2023)
  • FMR LLC Filed SC 13G/A on Morphic Holding, Inc., latest Aug 12, 2024 (4 filings since Feb 9, 2022)
  • Wellington Management Company Filed SC 13G/A on Morphic Holding, Inc., latest Aug 7, 2024 (3 filings since Feb 8, 2024)
  • EcoR1 Capital, LLC Filed SC 13G on Morphic Holding, Inc., latest May 3, 2024 (4 filings since Feb 14, 2022)
  • Artal International S.C.A. Filed SC 13G/A on Morphic Holding, Inc., latest Feb 9, 2024 (3 filings since Feb 11, 2022)
  • Polaris Partners VII, L.P. Filed SC 13G/A on Morphic Holding, Inc., latest Feb 9, 2024 (2 filings since Feb 11, 2022)
  • BlackRock Filed SC 13G/A on Morphic Holding, Inc., latest Jan 26, 2024 (2 filings since Feb 3, 2023)
  • State Street Corporation Filed SC 13G on Morphic Holding, Inc., latest Jan 24, 2024
  • Timothy A. Springer Filed SC 13D on Morphic Holding, Inc., latest Oct 18, 2023
  • Novo Holdings A/S Filed SC 13D/A on Morphic Holding, Inc., latest Feb 22, 2022 (2 filings since Nov 1, 2021)
  • Omega Fund V, L.P. Filed SC 13G/A on Morphic Holding, Inc., latest Feb 14, 2022
  • Eli Lilly and Company Indianapolis, Indiana, United States
    • Morphic Holding, Inc. Waltham, Massachusetts, United States
      • Morphic Security Corporation Subsidiary · Massachusetts, United States
    • Eli Lilly (India) Subsidiary · Gurgaon, India
    • Eli Lilly (United Kingdom) Subsidiary · Basingstoke, United Kingdom
    • ImClone Systems Subsidiary
    • Lilly (China) Subsidiary · Shanghai, People's Republic of China
    • Lilly France Subsidiary · Neuilly-sur-Seine, France
    • Adverum Biotechnologies, Inc. Subsidiary · Delaware, United States
    • Adverum NC, LLC Subsidiary · Delaware, United States
    • Akouos, Inc. Subsidiary · Delaware, United States
    • Alnara Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Annapurna Therapeutics, Ltd. Subsidiary · Ireland
    • Aparito Espanya S.L. Subsidiary · Spain
    • Aparito LLC Subsidiary · Delaware, United States
    • ARMO Biosciences, Inc. Subsidiary · Delaware, United States
    • Avalanche Australia Pty Ltd. Subsidiary · Australia
    • Avid Radiopharmaceuticals, Inc. Subsidiary · Delaware, United States
    • CoLucid Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Compania Farmaceutica Eli Lilly de Centro America S.A. Subsidiary · Guatemala
    • CPD 4, Inc. Subsidiary · Delaware, United States
    • Dermira, Inc. Subsidiary · Delaware, United States
    • DICE Alpha Inc. Subsidiary · Delaware, United States
    • DICE Molecules SV, Inc. Subsidiary · Delaware, United States
    • DICE Therapeutics, Inc. Subsidiary · Delaware, United States
    • Disarm Therapeutics Inc. Subsidiary · Delaware, United States
    • Dista Ilac Ticaret Limited Sirketi Subsidiary · Turkey
    • and 138 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Morphic Holding, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$9.0M6 Dec 31, 2023$7.3M6 Dec 31, 2022+23.8%
Accumulated depreciation$6.3M6 Dec 31, 2023$5.2M6 Dec 31, 2022+21.1%
Property and equipment, net$2.8M6 Dec 31, 2023$2.1M6 Dec 31, 2022+30.6%
Operating-lease assets (leased space)$2.1M6 Dec 31, 2023$3.5M6 Dec 31, 2022−39.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$58.6M6 Dec 31, 2023$59.3M6 Dec 31, 2022−1.2%
Debt securities available for sale$645.8M6 Dec 31, 2023$289.0M6 Dec 31, 2022+123.5%

Leadership

Who has led Morphic Holding, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Praveen P. Tipirneni2019–2024

President

  1. Praveen P. Tipirneni2019–2024

Chief financial officer

  1. Marc Schegerin2020–2024

Chief operating officer

  1. Marc Schegerin2020–2024
20202025
Board members and other officers (17)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerBruce E. Rogers named Mar 1, 202331
  • Executive OfficerRobert E. Farrell named Mar 1, 202331

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Morphic Security Corporation Massachusetts4
  • Morphic Therapeutic UK Ltd United Kingdom4
  • Morphic Therapeutic, Inc. Delaware4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Morphic Holding, LLCJul 13, 2016 to Oct 1, 20183

Timeline

  1. Aug 16, 20248-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer32
  2. Jul 8, 20248-K Entered a material agreement; Other events33
  3. Jun 5, 20248-K Shareholder vote34
  4. Apr 26, 20248-K Entered a material agreement; Ended a material agreement35
  5. Apr 25, 20248-K Results of operations36
  6. Mar 12, 20248-K Regulation FD disclosure37
  7. Feb 22, 20248-K Results of operations38
  8. Jan 12, 20248-K Results of operations; Regulation FD disclosure39
  9. Jan 3, 20248-K Executive or director change40
  10. Dec 6, 20238-K Code of ethics changed41
  11. Nov 3, 20238-K Results of operations; Executive or director change42
  12. Oct 12, 20238-K Results of operations; Other events43
  13. Jun 26, 2019New chief executive Praveen P. Tipirneni becomes CEO13

Calendar

When it reported results

  1. Apr 25, 2024Reported quarterly or annual results36
  2. Feb 22, 2024Reported quarterly or annual results38
  3. Jan 12, 2024Reported quarterly or annual results39
  4. Nov 3, 2023Reported quarterly or annual results42
  5. Oct 12, 2023Reported quarterly or annual results43
  6. Aug 3, 2023Reported quarterly or annual results44
  7. Apr 25, 2023Reported quarterly or annual results45
  8. Feb 23, 2023Reported quarterly or annual results46

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

222 filings to the SEC since October 2021: 3 annual reports, 9 quarterly reports, 31 major events, 108 insider forms, 26 large holders, 1 private raises, 44 other. The latest 20:

  1. Nov 14, 2024SC 13G/A MORPHIC HOLDING, INC. EDGAR
  2. Aug 26, 202415-12G EDGAR
  3. Aug 21, 20244 EDGAR
  4. Aug 20, 20244 EDGAR
  5. Aug 20, 20244 EDGAR
  6. Aug 20, 20244 EDGAR
  7. Aug 20, 20244 EDGAR
  8. Aug 20, 20244 EDGAR
  9. Aug 20, 20244 EDGAR
  10. Aug 20, 20244 EDGAR
  11. Aug 20, 20244 EDGAR
  12. Aug 20, 20244 EDGAR
  13. Aug 20, 20244 EDGAR
  14. Aug 20, 20244 EDGAR
  15. Aug 20, 20244 EDGAR
  16. Aug 16, 2024S-8 POS EDGAR
  17. Aug 16, 2024S-8 POS EDGAR
  18. Aug 16, 2024S-8 POS EDGAR
  19. Aug 16, 2024S-8 POS EDGAR
  20. Aug 16, 2024S-8 POS EDGAR

The 222 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

43 open-market trades by officers, directors and large owners since October 2021: 3 buys and 40 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 8, 2024Rogers BrucePRESIDENTSale20,000$55.79$1.1MForm 4
Jul 8, 2024SCHEGERIN MARCCFO and COOSale43,936$55.80$2.5MForm 4
Jul 8, 2024Tipirneni Praveen P.President and CEOSale21,582$55.79$1.2MForm 4
Jul 8, 2024Farrell Robert E JrSVP Finance and CAOSale30,272$55.80$1.7MForm 4
Jul 8, 2024DeVaul WilliamGeneral Counsel and SecretarySale10,000$55.79$557.9KForm 4
Jan 16, 2024Tipirneni Praveen P.President and CEOSale13,923$27.49$382.7KForm 4
Jan 16, 2024SCHEGERIN MARCCFO and COOSale6,041$27.49$166.1KForm 4
Jan 16, 2024Rogers BrucePRESIDENTSale6,314$27.49$173.6KForm 4
Jan 16, 2024Farrell Robert E JrSVP Finance and CAOSale5,089$27.49$139.9KForm 4
Jan 16, 2024DeVaul WilliamGeneral Counsel and SecretarySale4,509$27.49$124.0KForm 4
Nov 13, 2023Edwards MartinDirectorBuy2,376$20.54$48.8KForm 4
Nov 13, 2023SLATTERY JOSEPH PDirectorBuy2,400$20.60$49.4KForm 4
Sep 7, 2023SCHEGERIN MARCCFO and COOSale20,000$54.34$1.1MForm 4
Aug 1, 2023Tipirneni Praveen P.President and CEOSale3,597$57.04$205.2KForm 4
Jul 3, 2023Tipirneni Praveen P.President and CEOSale3,597$57.04$205.2KForm 4
Jun 12, 2023Tipirneni Praveen P.President and CEOSale840$63.01$52.9KForm 4
Jun 7, 2023DeVaul WilliamGeneral Counsel and SecretarySale7,756$60.05$465.7KForm 4
Jun 1, 2023Tipirneni Praveen P.President and CEOSale3,597$57.14$205.5KForm 4
May 24, 2023DeVaul WilliamGeneral Counsel and SecretarySale100$60.00$6.0KForm 4
May 23, 2023Farrell Robert E JrSVP Finance and CAOSale10,000$60.00$600.0KForm 4

All 43 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Feb 15, 2023Raised $100 million in a private offering of equity Form D: $100 million offered in all Form D

SEC filer profile

How Morphic Holding, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMorphic Holding, Inc.1
  • CIK0001679363
  • Employer ID (EIN)47-38787721
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address35 Gatehouse Drive A2, Waltham, MA 024511
  • Phone(781) 996-09551
  • Shares outstanding50,224,699 as of Jul 23, 202411
  • Public float$2.1B as of Jun 30, 20236
  • On EDGAR sinceJul 13, 20161
  • Filings480 in all: 4 (231), 8-K (54), SC 13G/A (26), 3 (23), 10-Q (16), 144 (14), SC 13G (13), 4/A (11)1
    All 46 form types

    SC 13D/A (7), S-8 (6), S-8 POS (6), 10-K (5), 424B5 (5), CORRESP (5), DEF 14A (5), DEFA14A (5), D (3), S-3ASR (3), SC 13D (3), SC 14D9/A (3), SC TO-T/A (3), UPLOAD (3), DRSLTR (2), EFFECT (2), POSASR (2), S-1/A (2), S-3 (2), SEC STAFF LETTER (2), 10-Q/A (1), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), ARS (1), CERT (1), DRS (1), DRS/A (1), PRE 14A (1), RW (1), RW WD (1), S-1 (1), S-1MEF (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Feb 22, 2024
    Quarterly report (10-Q) Jul 25, 2024
    Proxy statement (DEF 14A) Apr 25, 2024
    Latest 8-K (8-K) Aug 16, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57